Compare AU
Compare CURE vs. IBAL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the iShares Balanced Esg ETF (IBAL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | IBAL | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 83 | 0 |
Median incremental investment | $619.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,467.76 | $0 |
Average age group | > 35 | N/A |
Key Summary
CURE | IBAL | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | IBAL.AX was created on 2022-08-15 by iShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. The Fund aims to provide investors with the performance of the various indices of the Underlying Funds in which the Fund invests, in proportion to a Balanced long term Strategic Asset Allocation . |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.96 %) Gilead Sciences Inc (2.80 %) | iShares Core MSCI Wld Ex Aus ESG ETF (20.82 %) iShares Core MSCI Australia ESG ETF (19.88 %) iShares Treasury ETF (18.97 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (99.97 %) Communication Services (0.03 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (47.38 %) Australia (36.02 %) Japan (3.94 %) |
Management fee | 0.45 % | 0.22 % |
Key Summary
CURE | IBAL | |
|---|---|---|
Issuer | Global X | iShares |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.22 % |
Price | $52.42 | $29.46 |
Size | $36.301 million | $12.205 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 1.30 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 16/08/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | IBAL | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 83 | 0 |
Median incremental investment | $619.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,467.76 | $0 |
Average age group | > 35 | N/A |
Pros and Cons
CURE | IBAL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | IBAL |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |